Head-To-Head Review: Executive Network Partnering (NYSE:ENPC) & Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD) and Executive Network Partnering (NYSE:ENPC) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Hyperion DeFi and Executive Network Partnering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	416.56%	-11.62%	-9.96%
Executive Network Partnering	N/A	-74.23%	-2.27%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Hyperion DeFi and Executive Network Partnering, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	2	0	2.00
Executive Network Partnering	0	0	0	0	0.00

Hyperion DeFi currently has a consensus target price of $7.20, suggesting a potential upside of 120.86%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, research analysts clearly believe Hyperion DeFi is more favorable than Executive Network Partnering.

Earnings & Valuation

This table compares Hyperion DeFi and Executive Network Partnering”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	62.54	-$45.31 million	($6.53)	-0.50
Executive Network Partnering	N/A	N/A	$1.47 million	N/A	N/A

Executive Network Partnering has lower revenue, but higher earnings than Hyperion DeFi.

Insider & Institutional Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 88.6% of Executive Network Partnering shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 0.2% of Executive Network Partnering shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Hyperion DeFi has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500. Comparatively, Executive Network Partnering has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500.

Summary

Hyperion DeFi beats Executive Network Partnering on 8 of the 11 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Executive Network Partnering

Executive Network Partnering Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar partnering transaction with one or more businesses. The company was incorporated in 2020 and is based in Boston, Massachusetts.